ReviewJournal of molecular medicine (Berlin, Germany)2012
Genetic variants in candidate genes influencing NAFLD progression.
Review in Journal of molecular medicine (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis.African health sciences · 2020Pooled it
- Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.Drug delivery and translational research · 2024Review
- Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression.Biomolecules · 2024Review
- Human Hepatic Stellate Cells: Isolation and Characterization.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.Inflammopharmacology · 2021Review
- BrainCells · 2021Article
- Molecular and cellular mechanisms of liver fibrosis and its regression.Nature reviews. Gastroenterology & hepatology · 2021Review
- The expression levels of CHI3L1 and IL15Rα correlate with TGM2 in duodenum biopsies of patients with celiac disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Denitrase activity ofExperimental and therapeutic medicine · 2019Article
- The genetic backgrounds in nonalcoholic fatty liver disease.Clinical journal of gastroenterology · 2018Review
- Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.Current molecular pharmacology · 2017Review
- Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice.BMC genomics · 2016Article
- Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients.Canadian journal of gastroenterology & hepatology · 2016Article
- Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World journal of gastroenterology · 2015Review
- Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.Frontiers in pharmacology · 2015Article
- Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?World journal of gastroenterology · 2014Review
- Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A morphological study.European journal of histochemistry : EJH · 2014Article
- PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice.Diabetologia · 2013Article
- Inhibition of apoptosis in the management of nonalcoholic fatty liver disease.World journal of gastrointestinal pharmacology and therapeutics · 2013Article
- Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a metabolic disorder including simple steatosis and nonalcoholic steatohepatitis (NASH). Advanced stages of NASH result ultimately in fibrosis, cirrhosis, and hepatocarcinoma. A diagnosis of NASH entails an increased risk of both liver-related and cardiovascular mortality as worsening of the metabolic syndrome. Because of its escalation, many investigations have been performed to elucidate the pathophysiologic origins of the disease progression. Human epidemiologic studies describing polymorphisms in a number of genes involved in metabolic dysfunctions have contributed to clarify the causes leading to the disease evolution. In this review, we attempt to outline critically the most recently identified genetic variants in NAFLD patients to identify possible risk factors promoting the progression of the disease. The evaluation of altered genotypes together with other clinical variables may facilitate the clinical management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.